Ignite Creation Date:
2024-05-06 @ 12:27 AM
Last Modification Date:
2024-10-26 @ 10:50 AM
Study NCT ID:
NCT01579279
Status:
TERMINATED
Last Update Posted:
2013-09-26
First Post:
2012-04-16
Brief Title:
A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain
Sponsor:
AbbVie prior sponsor Abbott
Organization:
AbbVie
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain
Status:
TERMINATED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic neuropathic pain People with diabetes can over time develop nerve damage throughout the body with symptoms such as pain tingling or numbness loss of feeling in the hands arms feet and legs
Detailed Description:
A double blind randomized active- and placebo-controlled 13-week study Duloxetine is added to evaluate assay sensitivity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-003939-56 | EUDRACT_NUMBER | None | None |